- Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta RM, Wang Y, Wang Y, DePeaux K, Poholek AC, and Delgoffe GM. “Metabolic stress induced by continuous stimulation under hypoxia rapidly promotes a terminally exhausted T cell state.” Nature Immunology 22, 206-215 (2021).
- Dayana B. Rivadeneira, Kristin DePeaux, Yiyang Wang, Aditi Kulkarni, Tracy Tabib, Ashley V. Menk, Padmavathi Sampath, Robert Lafyatis, Robert L. Ferris, Saumendra N. Sarkar, Stephen H. Thorne, and Greg M. Delgoffe. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity, 51 (2019), pp.548-560
- Dayana B. Rivadeneira and Greg M. Delgoffe. Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy. Clin Cancer Res January 31, 2018
- J.H. Seo, D.B. Rivadeneira, M.C. Caino, Y.C. Chae, D.W. Speicher, H.Y.Tang, V. Vaira, S. Bosari, A. Palleschi, P. Rampini, A.V. Kossenkov, L.R.Languino, D.C. Altieri. The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. 2016 PLoS Biology,14(7)
- Dayana B. Rivadeneira, M. Cecilia Caino, Jae Ho Seo, Alessia Angelin, Douglas C. Wallace, Lucia R. Languino and Dario C. Altieri. Mitochondrial respiration controlled by Survivin directs positional Organelle trafficking and tumor cell invasion. 2015 Science Signaling Aug 11;8(389) –Selected for cover
- Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-Pathway Perturbations with DCIS Recurrence Dependence on Tumor versus Tissue Microenvironment. 2011 Am J Pathol. 179:1171-8.
- Rivadeneira DB, Mayhew CM, Chellappagounder T, Sotillo E, Reed CA, Grana X, Knudsen ES. “Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Tumor Suppressor Pathway in Liver Tissue and Hepatoma Cells.” 2010 Gastroenterology 138:1920-1930
Iam a Research Assistant Professor, working under the mentorship of Dr. Greg M. Delgoffe in the Department of Immunology at the University of Pittsburgh. I obtained my PhD, at Thomas Jefferson University where I explored the various mechanisms underlying the uncontrolled proliferation observed in cancer cells focusing on the role of CDK4/6 inhibition as a therapeutic target. I completed my postdoctoral training with Dr. Dario Altieri at the Wistar Institute uncovering how mitochondrial dynamics can shape cancer cell fate. I am passionate about the role that metabolism plays both within cancer cells as well as the tumor microenvironment, so I decided to join the Delgoffe lab, as a postdoctoral fellow, to explore the role of cancer metabolism in tumor progression and immune evasion. During this time, I developed means by which the tumor microenvironment could be metabolically reprogrammed, with a specific focus on oncolytic viruses, which not only lyse tumor cells and promote immune infiltration, but also provide the opportunity for delivery of genetic cargo. We found that metabolic modulators, like the adipokine leptin, could be encoded in the virus for therapeutic benefit.
My current research focuses on the role that oxidative stress within the tumor microenvironment can change immune fate and function, generating novel mouse models and in vitro strategies to uncover the role that oxygen tension and metabolic stress can play in immune fate.